Gene therapy for Parkinson's disease: Recent achievements and remaining challenges

Histology and Histopathology

Volumn 16, Issue 4, 2001, Pages 1225-1238

  Castro, M G ^a   David, A ^a   Hurtado Lorenzo, A ^a   Suwelack, D ^a   Millan, E ^a   Verakis, T ^a   Xiong, W D ^a   Yuan, X P ^a   Lowenstein, P R ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Adenovirus; GDNF; Gene delivery; Neurodegenerative disorders; Parkinson's disease; Viral vectors

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIPARKINSON AGENT; DRUG CARRIER; NUCLEIC ACID; OXIDOPAMINE; VIRUS VECTOR;

BLOOD BRAIN BARRIER; BRAIN; DRUG TARGETING; EXPERIMENTAL MODEL; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNE RESPONSE; MITOSIS; NERVE CELL; NONHUMAN; PARKINSON DISEASE; REVIEW; SKULL; TARGET CELL; TRANSGENE;

ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; PARKINSON DISEASE;

ADENOVIRIDAE;

EID: 0034782221     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Regulatable systems: Applications in gene therapy and replicating viruses
2. Levodopa. Is toxicity a myth?
3. Prognosis with Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research group
4. Gene transfer systems derived from Visna virus: Analysis of virus production and infectivity
5. Chronic systemic pesticide exposure reproduces features of Parkinson's disease
6. Experimental models of Parkinson's disease: From the static to the dynamic
7. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: Evolution of motor symptoms in the monkey
8. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioural impairment in a rat model of Parkinson disease
9. Functional changes of the basal ganglia circuitry in Parkinson's disease
10. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vectors
11. Long-term expression of a foreign gene from a unique position in the latent herpes simplex virus genome
12. IL-1 mediates a rapid inflammatory response following adenoviral vector delivery into the brain
13. Gene therapy strategies for intracranial tumours: Glioma and pituitary adenomas
14. Regulatable and cell-type specific transgene expression in glial cells: Prospects for gene therapy for neurological disorders
15. Persistence in muscle of an adenoviral vector that lacks all viral genes
16. Behavioural and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding Glial Cell Line-Derived Neurotrophic factor
17. Dopaminergic neurons protected from degeneration by GDNF gene therapy
18. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes
19. Gene transfer and therapy clinical trials - Update. Part 2: Gene delivery systems used and genes transferred
20. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat
21. Long term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus mediated gene transfer to a rat model of Parkinson's disease
22. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors
23. Production of first generation adenovirus vectors: A review
24. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease
25. Chronic brain inflammation and persistent HSV1-TK expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials
26. A third-generation lentivirus vector with a conditional packaging system
27. Long term behavioural recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase
28. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine model of Parkinson's disease
29. A novel MPTP primate model of Parkinson's disease: Neurochemical and clinical changes
30. Neurogenesis in the adult human hippocampus
31. A Drosophila model of Parkinson's disease
32. Transplantation of embryonic dopamine neurons for severe Parkinson's disease
33. Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo
34. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
35. Highly controlled gene expression using combinations of a tissue-specific promoter, recombinant adenovirus and a tetracycline-regulatable transcription factor
36. Extensive β-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to the brain
37. Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration
38. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: Neuroprotective strategies
39. Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element
40. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral gene
41. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system
42. Importance of familial Parkinson's disease and parkinsonism to the understanding of nigral degeneration in sporadic Parkinson's disease
43. 6-Hydroxydopamine induced apoptosis of dopaminergic cells in the rat substantia nigra
44. Direct intracerebral gene transfer of adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease
45. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinicopathological study of 100 cases
46. Adenovirus-mediated gene therapy for Parkinson's disease: Neuroprotective properties of Shh signal. 4th Annual Meeting of the American Society of Gene Therapy. 30th May - 3rd June, Washington Convention Center, Seattle, Washington, U.S.A.
47. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity
48. Minimal requirements for efficient transduction of dividing and nondividing human cells by feline immunodeficiency virus vectors
49. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
50. A packaging cell line for lentivirus vectors
51. Lentiviral vectors: Regulated gene expression
52. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain
53. Characterization of behavioural and neurodegenerative changes following partial lesions of nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat
54. A stable system for the high-titer production of multiply attenuated lentiviral vectors
55. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase
56. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
57. Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic laterial sclerosis
58. Genetic targeting of adenoviral vectors
59. Gene therapy using herpes simplex virus-based vectors
60. Dopaminergic neuronal degeration and motor impairment following lesion by intrastriatal 6-hydroxydopamine in the rat
61. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease
62. Therapeutic applications of viral vectors
63. Experimental models of Parkinson disease
64. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell lin-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats
65. Characterization of instrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-Cyclohydrolase I in a rat model of Parkinson's disease
66. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease
67. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vitro
68. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders
69. Sonic hedgehog promotes the survival of specific CNS neuron populations and protects these cells from toxic insult in vitro
70. Neuropharmacologic aspects of apoptosis: Significance for neurodegenerative diseases
71. Stable and efficient gene transfer into the retina using HIV-based lentiviral vector
72. Development of a self-inactivating lentivirus vector
73. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver directed gene transfer in baboons
74. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity
75. An 18F dopa-PET and clinical study of the rate of progression in Parkinson's disease
76. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene
77. Editorial: Gene therapy for Parkinson's disease: Current knowledge and future perspective
78. Defective RNA packaging is responsible for low transduction efficiency of CAEV-based vectors
79. Lack of functional receptors is the only barrier that prevents caprine arthritis-encephalitis virus from infecting human cells
80. Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo
81. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
82. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector
83. Basal ganglia, Parkinson's disease and levodopa therapy
84. Gene transfer vectors derived from equine infectious anemia virus
85. A helper-dependant adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal
86. The catechol-o-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease
87. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors
88. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
89. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector
90. Chimeric vectors - The best of both worlds?
91. Integration of murine leukaemia virus DNA depends on mitosis
92. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member Neublastin/Artemin
93. Modifying the host range properties of retroviral vectors
94. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in rat
95. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
96. Young-onset Parkinson's disease revisited - Clinical features, natural history, and mortality
97. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae
98. Adenovirus-mediated transcriptional targeting in the adult brain and pituitary: Cell-type specific and inducible transgene expression is promoter dependent
99. Mouse models of alpha-synucleinopathy and Lewy pathology
100. Viral vectors for gene delivery and gene therapy within the endocrine system
101. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice
102. Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient mice
103. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first generation, but not with high-capacity adenovirus vectors: Towards realistic long-term neurological gene therapy for chronic diseases
104. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain
105. Pre-existing anti-adenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high capacity adenovirus vectors
106. Experimental models of Parkinson's disease: Insights from many models
107. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons
108. An efficient, in vitro-evolved FLPe enables scalable production of helper-dependent adenoviral vectors with negligible helper contamination
109. Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of nigrostriatal dopamine system
110. Neuropathology in mice expressing human alpha-synuclein
111. Gene therapy: Promises, problems and prospects
112. Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis
113. Immune responses to adenoviral vectors in the nervous system
114. Development of a novel trans-lentiviral vector that affords predictable safety
115. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors
116. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hyroxydopamine-induced degeneration of neurons in the substantia nigra in vivo
117. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy
118. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
119. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses
120. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
121. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery
122. Woodchuck hepatitis virus post-transcriptional regulatory element enhances expression of transgenes delivered by retroviral vectors